Topical fluoxetine as a novel therapeutic that improves wound healing in diabetic mice

Chuong Minh Nguyen, Danielle Marie Tartar, Michelle Dawn Bagood, Michelle So, Alan Vu Nguyen, Anthony Gallegos, Daniel Fregoso, Jorge Serrano, Duc Nguyen, Doniz Degovics, Andrew Adams, Benjamin Harouni, Jaime Joel Fuentes, Melanie G. Gareau, Robert William Crawford, Athena M. Soulika, Roslyn Rivkah Isseroff

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Diabetic foot ulcers represent a significant source of morbidity in the U.S., with rapidly escalating costs to the health care system. Multiple pathophysiological disturbances converge to result in delayed epithelialization and persistent inflammation. Serotonin (5-hydroxytryptamine [5-HT]) and the selective serotonin reuptake inhibitor fluoxetine (FLX) have both been shown to have immunomodulatory effects. Here we extend their utility as a therapeutic alternative for nonhealing diabetic wounds by demonstrating their ability to interact with multiple pathways involved in wound healing. We show that topically applied FLX improves cutaneous wound healing in vivo. Mechanistically, we demonstrate that FLX not only increases keratinocyte migration but also shifts the local immune milieu toward a less inflammatory phenotype in vivo without altering behavior. By targeting the serotonin pathway in wound healing, we demonstrate the potential of repurposing FLX as a safe topical for the challenging clinical problem of diabetic wounds.

Original languageEnglish (US)
Pages (from-to)1499-1507
Number of pages9
Issue number7
StatePublished - Jan 1 2019

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Topical fluoxetine as a novel therapeutic that improves wound healing in diabetic mice'. Together they form a unique fingerprint.

Cite this